Dihydrexidine - The first full dopamine D1 receptor agonist

CNS Drug Reviews

Volumn 10, Issue 3, 2004, Pages 230-242

  Salmi, Peter ^a   Isacson, Ruben ^a   Kull, Björn ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Dihydrexidine; Dopamine; Dopamine agonist; Dopamine D1 receptor agonist

Indexed keywords

1 AMINOMETHYL 5,6 DIHYDROXY 3 PHENYLISOCHROMAN; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 4,6,6A,7,8,12B HEXAHYDRO 7 METHYLINDOLO[4,3 AB]PHENANTHRIDINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADROGOLIDE; AMPHETAMINE; COCAINE; CYCLIC AMP; DIHYDREXIDINE; DOPAMINE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; PHENANTHRIDINE DERIVATIVE; SKF 89626; SPIPERONE; TRITIUM;

AGING; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ATTENTION DEFICIT DISORDER; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; COGNITION; COGNITIVE DEFECT; CORE TEMPERATURE; DOPAMINERGIC SYSTEM; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EMOTION; HUMAN; LOCOMOTION; MENTAL DISEASE; MOTOR PERFORMANCE; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NONHUMAN; PARKINSON DISEASE; RAT; REVIEW; SCHIZOPHRENIA; SOCIAL BEHAVIOR; STEREOTYPY; SUBSTANCE ABUSE;

EID: 6344231535     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2004.tb00024.x     Document Type: Review

References (63)

1. 1 receptor agonist: A microstructural analysis of its effects on feeding and other behaviour in the rat. Behav Pharmacol 1994;5:210-218.
2. 1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 1994;116:143-151.
3. Beninger RJ. The role of dopamine in locomotor activity and learning. Brain Res 1983;287:173-196.
4. 1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 1998;21:339-343.
5. 1 full agonist. J Med Chem 1990;33:1756-1764.
6. 1 receptor stimulation. Science 2000;287:2020-2022.
7. 1 dopamine receptor agonist. Neuropsychopharmacology 1991;5:187-195.
8. 1 receptor. Eur J Pharmacol 1991;199:209-219.
9. 1-like" dopamine receptor agonists. Pharmacol Biochem Behav 1997;58:551-558.
10. Emilien G, Maloteaux JM, Geurts M, Hoogenberg K, Cragg S. Dopamine receptors-physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999;84:133-156.
11. Faunt JE, Crocker AD. The effects of selective dopamine receptor agonists and antagonists on body temperature in rats. Eur J Pharmacol 1987;133:243-247.
12. 1 agonist into the rat medial prefrontal cortex. Behav Neurosci 2001;115:934-939.
13. 1 dopamine receptor mediation of social and nonsocial emotional reactivity in mice: Effects of housing and strain difference in motor activity. Behav Neurosci 1997;111:424-434.
14. 1 agonist containing a rigid-beta-phenyldopamine pharmacophore. J Med Chem 1996;39:549-555.
15. 1 agonists in human caudate: Biochemical properties and therapeutic implications. Neuropharmacology 1995;34:481-488.
16. 1 receptor full agonists in rats trained to discriminate SKF 38393. Behav Pharmacol 2004;15:85-89.
17. Goulet M, Madras BK. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated monkeys. J Pharmacol Exp Ther 2000;292:714-724.
18. 1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (Berl) 1999;143:102-110.
19. Isacson R, Kull B, Wahlestedt C, Salmi P. A 68930 and dihydrexidine inhibit locomotor activity and d-amphetamine-induced hyperactivity in rats: A role of inhibitory dopamine D(1/5) receptors in the prefrontal cortex? Neuroscience 2004;124:33-42.
20. 1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav 1995;51:617-622.
21. 1 receptor agonist with antiparkinsonian activity in marmosets. Eur J Pharmacol 1992;229:203-209.
22. 2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 2002;301:1179-1189.
23. 2 receptors. Soc Neurosci Abstr 1996;22:1769.
24. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997;11:123-131.
25. Lee TF, Mora F, Myers RD. Dopamine and thermoregulation: An evaluation with special reference to dopaminergic pathways. Neurosci Biobehav Rev 1985;9:589-598.
26. 1 dopamine receptors: Studies in mice selectively bred for high and low levels of aggression. Neuropsychopharmacology 1994;10:115-122.
27. Lovenberg TW, Brewster WK, Mottola DM, et al. Dihydrexidine, a novel selective high potency full dopamine D-1 receptor agonist. Eur J Pharmacol 1989;166:111-113.
28. 1 receptors. J Neurochem 1991;57:1563-1569.
29. 1 dopamine receptors. Curr Opin Investig Drugs 2001;2:1582-1591.
30. 1 receptor agonists as antiparkinson drugs. Trends Pharmacol Sci 1998;19:255-256.
31. Meyer-Lindenberg A, Miletich RS, Kohn PD, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002;5:267-271.
32. 1 gene to attention-deficit/hyperactivity disorder. Mol Psychiatry 2004;9:500-509.
33. Molloy AG, Waddington JL. Sniffing, rearing and locomotor responses to the D-1 dopamine agonist R-SKF 38393 and to apomorphine: Differential interactions with the selective D-1 and D-2 antagonists SCH 23390 and metoclopramide. Eur J Pharmacol 1985;108:305-308.
34. Molloy AG, Waddington JL. Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SKF 38393 and its R- and S-enantiomers in the intact adult rat. Psychopharmacology (Berl) 1987;92:164-168.
35. 1 dopamine receptor agonist. J Pharmacol Exp Ther 1992;262:383-393.
36. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 2002;301:1166-1178.
37. 1 dopamine receptor agonists: Pharmacophore assessment and receptor mapping. J Med Chem 1996;39:285-296.
38. 2 receptor agonist talipexole in the rat. Pharmacol Biochem Behav 1992;43:993-997.
39. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;61:53-83.
40. 1 receptors in schizophrenia revealed by PET. Nature 1997;385:634-636.
41. Pycock CJ, Kerwin RW, Carter CJ. Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature 1980;286:74-76.
42. Radcliffe RA, Erwin VG. Alterations in locomotor activity after microinjections of GBR-12909, selective dopamine antagonists or neurotensin into the medial prefrontal cortex. J Pharmacol Exp Ther 1996;277:1467-1476.
43. 1 receptor selectivity and comparisons to the partial agonist SKF 38393. J Pharmacol Exp Ther 1998;286:272-281.
44. 2/3 receptors in rat thermoregulation. Brain Res 1998;781:188-193.
45. 1 receptors. Neurosci Lett 1997;236:57-59.
46. 1 receptor agonist A 68930 on rat open-field behavior. Neuroreport 2000;11:1269-1272.
47. 2 receptors in the regulation of body temperature in the rat. Eur J Pharmacol 1993;236:395-400.
48. 1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 1994;71:515-528.
49. 1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys. Brain Res 1994;663:140-144.
50. 2-like dopamine receptor agonists. Science 1996;271:1586-1589.
51. 2, receptors. Psychopharmacology (Berl) 1996;123:303-306.
52. 1 receptor agonists A-86929 and ABT-431. Eur J Pharmacol 1996;317:183-190.
53. 1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats. Pharmacol Biochem Behav 1997;58:477-483.
54. 1 agonist, reduces MPTP-induced parkinsonism in monkeys. Eur J Pharmacol 1991;199:389-391.
55. Thompson TL, Moss RL. In vivo stimulated dopamine release in the nucleus accumbens: Modulation by the prefrontal cortex. Brain Res 1995;686:93-98.
56. Tzschentke TM, Schmidt WJ. Functional relationship among medial prefrontal cortex, nucleus accumbens, and ventral tegmental area in locomotion and reward. Crit Rev Neurobiol 2000;14:131-142.
57. Verma A, Kulkarni SK. Dopamine receptor mediated hypothermic action of B-HT 920 in rats. J Pharm Pharmacol 1991;43:421-424.
58. 1 receptors: Efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol 1993;242:165-172.
59. 1 dopamine receptor agonists. Synapse 1995;21:177-187.
60. 2 systems and spatial working memory in rats. Neuroscience 1999;89:743-749.
61. Witkin JM, Nichols DE, Terry P, Katz JL. Behavioral effects of selective dopaminergic compounds in rats discriminating cocaine injections. J Pharmacol Exp Ther 1991;257:706-713.
62. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 1994;79:729-742.
63. 1 dopamine receptor agonists mediate activation of p38 mitogen-activated protein kinase and c-Jun amino-terminal kinase by a protein kinase A-dependent mechanism in SK-N-MC human neuroblastoma cells. Mol Pharmacol 1998;54:453-458.